Husseini K. Manji, MD, FRCPC is Professor, Oxford University, Visiting Professor, Duke Universities, and co-chair, UK Govt Mental Health Mission. He is past Global Head for Neuroscience at J&J and was previously Chief of NIH Laboratory of Molecular Pathophysiology, and Director of NIH Mood and Anxiety Disorders Program, the largest program of its kind in the world. He has been inducted into the National Academy of Medicine (NAM), is a member of the NIH Novel/Exceptional Technology and Research Advisory Committee, the World Dementia Council, is co-chair of the Board of the Healthy Brains Global Initiative, and is recent chair of the NAM Neuroscience, Behavior, Brain Function group.
Dr. Manji has helped to discover/develop, and launch several new medications for serious neuropsychiatric/neurodegenerative disorders, including the first novel antidepressant mechanism in over 30 years, the first ever Neuroscience medication to be granted US FDA “breakthrough therapy” designation and novel treatments for schizophrenia, and Alzheimer’s disease, others. He has received numerous International awards, including the NAM International Mental Health Award, NIMH Director’s Career Award for Significant Scientific Achievement, PhRMA Excellence in Research Award, A. E. Bennett & Ziskind-Somerfeld Awards for Neuropsychiatric Research, NARSAD Mood Disorders Prize, Mogens Schou Distinguished Research Award, ACNP’s Joel Elkes Award for Distinguished Research, DBSA Klerman Senior Distinguished Researcher Award, the Global Health & the Arts Award of Recognition, and has also been recognized as one of 14 inaugural “Health Heroes” by Oprah magazine. He has published extensively on the molecular and cellular neurobiology of severe neuropsychiatric/neurodegenerative disorders and development of novel therapeutics, with over 350 publications in leading peer-reviewed journals (> 50,000 citations; H-index:126)